Scientists dig into the DNA of drug-resistant lung cancers to find hidden clues
NCT ID NCT07122882
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study enrolls 40 people with non-small cell lung cancer whose tumors have stopped responding to targeted therapy (tyrosine kinase inhibitors). Researchers will analyze the tumors' full genetic code and RNA to find new resistance mechanisms. The goal is to better understand why these cancers become resistant, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal new genetic reasons why lung cancers become resistant to targeted therapies, pointing toward future treatment strategies.
- What could go wrong
- This is a small, early-stage observational study (40 people) that does not test a new treatment. It may not find clear or actionable resistance mechanisms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK FUSION-POSITIVE SOLID OR CNS TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Memorial Hospital Linkou Branch
Taoyuan, 333, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail targets Hard-to-Treat colorectal cancer mutation
- New drug targets tough cancers in early trial
- New drug cocktail shows promise against tough lung cancer before surgery
- Brain tumor trial combines radiation with targeted drugs and immunotherapy
- New combo targets lung cancer brain tumors in 60-patient trial
- New study tracks how melanoma patients use a smartphone app during targeted treatment